Arbutus Biopharma (ABUS)

• Market cap: $595M
• 1 day: 2.94%
• 5 days: 0.96%
• 1 month: -3.96%
• 3 months: -1.56%
• 6 months: -23.54%
• Year to date: -4.26%
• 1 year: 13.31%
• 5 years: 164.71%
• 10 years: -83.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Employees: 73

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

32% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 41

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

7% more funds holding

Funds holding: 142 [Q3] → 152 (+10) [Q4]

1.73% more ownership

Funds ownership: 53.38% [Q3] → 55.11% (+1.73%) [Q4]

2% more call options, than puts

Call options by funds: $2.41M | Put options by funds: $2.35M

12% less capital invested

Capital invested by funds: $388M [Q3] → $341M (-$47M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 59% upside
• Avg. target: $5 59% upside
• High target: $5 59% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Keay Nakae 13% 1-year accuracy 9 / 72 met price target	59% upside $5	Buy Maintained	28 Mar 2025
HC Wainwright & Co. Ed Arce 33% 1-year accuracy 50 / 152 met price target	59% upside $5	Buy Reiterated	21 Jan 2025